Free Trial
NYSE:ANVS

Annovis Bio (ANVS) Stock Price, News & Analysis

Annovis Bio logo
$2.42 +0.38 (+18.63%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$2.50 +0.09 (+3.51%)
As of 08:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Annovis Bio Stock (NYSE:ANVS)

Key Stats

Today's Range
$2.04
$2.58
50-Day Range
$1.21
$2.42
52-Week Range
$1.11
$17.88
Volume
1.43 million shs
Average Volume
718,497 shs
Market Capitalization
$47.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.75
Consensus Rating
Buy

Company Overview

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Annovis Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

ANVS MarketRank™: 

Annovis Bio scored higher than 32% of companies evaluated by MarketBeat, and ranked 789th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Annovis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Annovis Bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Annovis Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Annovis Bio are expected to grow in the coming year, from ($2.19) to ($1.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Annovis Bio is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Annovis Bio is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Annovis Bio's valuation and earnings.
  • Percentage of Shares Shorted

    20.34% of the float of Annovis Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Annovis Bio has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Annovis Bio has recently increased by 0.51%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Annovis Bio does not currently pay a dividend.

  • Dividend Growth

    Annovis Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.34% of the float of Annovis Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Annovis Bio has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Annovis Bio has recently increased by 0.51%, indicating that investor sentiment is decreasing.
  • Search Interest

    2 people have searched for ANVS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Annovis Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.80% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.83% of the stock of Annovis Bio is held by institutions.

  • Read more about Annovis Bio's insider trading history.
Receive ANVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

ANVS Stock News Headlines

Do You Believe In President Trump? Answer This 1 Question
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
Annovis Bio stellt neuen Direktor für Biostatistik
See More Headlines

ANVS Stock Analysis - Frequently Asked Questions

Annovis Bio's stock was trading at $5.03 at the beginning of the year. Since then, ANVS stock has decreased by 51.9% and is now trading at $2.42.
View the best growth stocks for 2025 here
.

Annovis Bio, Inc. (NYSE:ANVS) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.15.

Annovis Bio (ANVS) raised $10 million in an IPO on Wednesday, January 29th 2020. The company issued 1,400,000 shares at $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO.

Top institutional shareholders of Annovis Bio include Warberg Asset Management LLC (0.27%), Lokken Investment Group LLC (0.21%) and Simplex Trading LLC.
View institutional ownership trends
.

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/13/2025
Today
5/28/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ANVS
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.75
High Stock Price Target
$67.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+1,336.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$56.20 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.73) per share
Price / Book
-3.32

Miscellaneous

Free Float
9,638,000
Market Cap
$47.16 million
Optionable
Optionable
Beta
1.46
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSE:ANVS) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners